title: Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses.
abstract: Clinical studies over the past several years have reported that metastasis-free survival times in humans and dogs with osteosarcoma are significantly increased in patients that develop chronic bacterial osteomyelitis at their surgical site. However, the immunological mechanism by which osteomyelitis may suppress tumor growth has not been investigated. Therefore, we used a mouse model of osteomyelitis to assess the effects of bone infection on innate immunity and tumor growth. A chronic Staphylococcal osteomyelitis model was established in C3H mice and the effects of infection on tumor growth of syngeneic DLM8 osteosarcoma were assessed. The effects of infection on tumor angiogenesis and innate immunity, including NK cell and monocyte responses, were assessed. We found that osteomyelitis significantly inhibited the growth of tumors in mice, and that the effect was independent of the infecting bacterial type, tumor type, or mouse strain. Depletion of NK cells or monocytes reversed the antitumor activity elicited by infection. Moreover, infected mice had a significant increase in circulating monocytes and numbers of tumor associated macrophages. Infection suppressed tumor angiogenesis but did not affect the numbers of circulating endothelial cells. Therefore, we concluded that chronic localized bacterial infection could elicit significant systemic antitumor activity dependent on NK cells and macrophages.
authors.affiliation: Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Ft. Collins, 80523, USA. jsottnik@rams.colostate.edu
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Sottnik
authors.forename: Lance W
authors.initials: LW
authors.lastname: U'Ren
authors.forename: Douglas H
authors.initials: DH
authors.lastname: Thamm
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Withrow
authors.forename: Steven W
authors.initials: SW
authors.lastname: Dow
mesh_terms: D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D009000:Monocytes / Q000276:immunology; D009369:Neoplasms; D009389:Neovascularization, Pathologic; D010019:Osteomyelitis / Q000150:complications*; D012516:Osteosarcoma / Q000150:complications* / Q000276:immunology* / Q000473:pathology; D013203:Staphylococcal Infections / Q000150:complications*
references.citation: Exp Hematol. 2006 Oct;34(10):1393-402
references.pmid: 16982332
references.citation: N Engl J Med. 1986 Dec 25;315(26):1650-9
references.pmid: 3537791
references.citation: J Antimicrob Chemother. 2002 Aug;50(2):289-92
references.pmid: 12161415
references.citation: Nat Rev Cancer. 2009 Jan;9(1):64-71
references.pmid: 19104515
references.citation: Int J Cancer. 2008 Feb 15;122(4):930-5
references.pmid: 17960612
references.citation: J Clin Invest. 1995 Dec;96(6):2578-82
references.pmid: 8675621
references.citation: J Leukoc Biol. 2007 Aug;82(2):244-52
references.pmid: 17475785
references.citation: J Immunother (1991). 1992 Jul;12(1):13-8
references.pmid: 1637780
references.citation: Immunol Cell Biol. 2009 Jan;87(1):30-8
references.pmid: 19048016
references.citation: J Clin Invest. 1996 Jun 15;97(12):2722-7
references.pmid: 8675682
references.citation: Cell Cycle. 2009 Mar 15;8(6):870-5
references.pmid: 19221501
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4827-34
references.pmid: 16000580
references.citation: J Leukoc Biol. 2007 May;81(5):1224-35
references.pmid: 17311932
references.citation: Clin Orthop Relat Res. 2008 Jun;466(6):1285-91
references.pmid: 18421536
references.citation: Immunobiology. 2006;211(6-8):609-18
references.pmid: 16920499
references.citation: J Exp Med. 2006 Mar 20;203(3):583-97
references.pmid: 16492803
references.citation: Immunity. 2003 Jul;19(1):71-82
references.pmid: 12871640
references.citation: Nat Rev Immunol. 2008 Dec;8(12):958-69
references.pmid: 19029990
references.citation: Cancer Sci. 2008 Aug;99(8):1595-602
references.pmid: 18754872
references.citation: J Immunol. 2004 Feb 1;172(3):1407-13
references.pmid: 14734716
references.citation: Mol Cancer Ther. 2008 Apr;7(4):788-99
references.pmid: 18375821
references.citation: J Immunol. 2004 Apr 1;172(7):4410-7
references.pmid: 15034056
references.citation: Cancer Lett. 2008 Aug 28;267(2):204-15
references.pmid: 18448242
references.citation: Curr Treat Options Oncol. 2008 Feb;9(1):67-80
references.pmid: 18449804
references.citation: Nat Rev Cancer. 2008 Feb;8(2):147-56
references.pmid: 18202698
references.citation: Nat Rev Cancer. 2006 Nov;6(11):835-45
references.pmid: 17036040
references.citation: Int J Cancer. 1998 May 4;76(3):418-22
references.pmid: 9579581
references.citation: J Immunol. 2001 May 15;166(10):5878-81
references.pmid: 11342601
references.citation: J Immunol. 1999 Aug 1;163(3):1552-61
references.pmid: 10415059
references.citation: Cancer Res. 2006 Jan 15;66(2):605-12
references.pmid: 16423985
references.citation: Trends Immunol. 2002 Nov;23(11):549-55
references.pmid: 12401408
references.citation: J Cell Biol. 1987 Mar;104(3):689-96
references.pmid: 3102503
references.citation: Cancer Immunol Immunother. 2009 May;58(5):769-75
references.pmid: 18633610
references.citation: Ann Surg Oncol. 2005 Dec;12(12):1073-83
references.pmid: 16252138
references.citation: Curr Oncol Rep. 2008 Jul;10(4):350-8
references.pmid: 18778562
references.citation: Bioessays. 2006 Jan;28(1):84-94
references.pmid: 16369949
references.citation: J Immunol Methods. 1994 Sep 14;174(1-2):83-93
references.pmid: 8083541
references.citation: Immunobiology. 1992 Jun;185(1):11-9
references.pmid: 1398738
references.citation: Cancer Biol Ther. 2003 Nov-Dec;2(6):687-93
references.pmid: 14688478
references.citation: Gene Ther. 2007 Nov;14(22):1573-86
references.pmid: 17898797
references.citation: Anticancer Res. 2007 Jan-Feb;27(1A):155-64
references.pmid: 17352227
references.citation: Cell Tissue Res. 1984;238(2):355-8
references.pmid: 6239690
references.citation: Gene Ther. 2009 Mar;16(3):329-39
references.pmid: 19177133
references.citation: Ann Surg. 1937 Jan;105(1):152-5
references.pmid: 17856903
references.citation: J Korean Med Sci. 2007 Sep;22 Suppl:S38-46
references.pmid: 17923753
references.citation: Br J Cancer. 2006 Aug 7;95(3):272-81
references.pmid: 16832418
references.citation: Cytokine Growth Factor Rev. 2003 Feb;14(1):67-77
references.pmid: 12485620
references.citation: Ann Surg Oncol. 2009 Jan;16(1):147-51
references.pmid: 18979137
references.citation: Nat Rev Cancer. 2008 Aug;8(8):618-31
references.pmid: 18633355
references.citation: J Invest Dermatol. 2007 Aug;127(8):2031-41
references.pmid: 17460736
references.citation: Ann Surg Oncol. 2007 Oct;14(10):2887-95
references.pmid: 17653803
references.citation: J Exp Med. 2007 May 14;204(5):1057-69
references.pmid: 17485518
references.citation: Blood. 1995 May 15;85(10):2910-7
references.pmid: 7742551
references.citation: J Immunol. 2009 Mar 1;182(5):3105-11
references.pmid: 19234207
references.citation: Cancer Immunol Immunother. 2007 Aug;56(8):1265-74
references.pmid: 17219148